☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
dual regimen
Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma
September 30, 2020
Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma
September 17, 2020
Janssen Receives EC's Approval for its Ebola Vaccine Dual Regimen
July 2, 2020
Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma
October 29, 2019
Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer
July 18, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.